Sacubitril/valsartan Mitigated Intermittent Hypoxia Related Intestinal Microbiota Alteration and Aortic Injury

Overview

Journal Sleep Breath

Publisher Springer

Date 2023 Jan 31

PMID 36719525

Authors

Jinfeng Wang

Hongxiang Zhang

Lijuan Wu

Dasheng Lu

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the influence of sacubitril valsartan sodium (SVS) on chronic intermittent hypoxia (IH) related gut microbiome composition alteration and aortic injury.

Methods: Experiments were performed using SD rats, which were divided into three groups: control, IH, and SVS group. O concentration was decreased to 7-8% at nadir approximately every 3 min in IH group (8 h per day for 6 weeks) or was left unchanged in control group. Rats in SVS group were orally gavaged with SVS at the dosage of 30 mg/kg/day (2 weeks after chronic IH exposure). At week 6, fecal and aortic samples were harvested for 16 s rDNA analysis and histological analysis, respectively.

Results: Principal coordinate analysis and non-metric multidimensional scaling analysis indicated that the bacterial community was altered by chronic IH exposure, while SVS treatment restored the intestinal microbial communities. Further analysis showed that IH decreased the relative abundance of Lactobacillus and Prevotella, while rats treated with SVS was enriched with Firmicutes, Bacilli, Prevotellaceae, and Lactobacillus, which was similar to control rats. Immunohistochemical staining showed that SVS prevented the upregulation of transforming growth factor-β1 and tumor necrosis factor-alpha in the aorta.

Conclusion: SVS prevented aortic adverse response to IH, possibly through modulating intestinal microbiota.

References

Devulapally K, Pongonis Jr R, Khayat R . OSA: the new cardiovascular disease: part II: Overview of cardiovascular diseases associated with obstructive sleep apnea. Heart Fail Rev. 2008; 14(3):155-64. PMC: 2698954. DOI: 10.1007/s10741-008-9101-2. View

Drager L, Bortolotto L, Lorenzi M, Figueiredo A, Krieger E, Lorenzi-Filho G . Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005; 172(5):613-8. DOI: 10.1164/rccm.200503-340OC. View

Drager L, Polotsky V, Lorenzi-Filho G . Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011; 140(2):534-542. PMC: 3198492. DOI: 10.1378/chest.10-2223. View

Ma L, Zhang J, Liu Y . Roles and Mechanisms of Obstructive Sleep Apnea-Hypopnea Syndrome and Chronic Intermittent Hypoxia in Atherosclerosis: Evidence and Prospective. Oxid Med Cell Longev. 2016; 2016:8215082. PMC: 4884866. DOI: 10.1155/2016/8215082. View

Tang W, Kitai T, Hazen S . Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017; 120(7):1183-1196. PMC: 5390330. DOI: 10.1161/CIRCRESAHA.117.309715. View

Farre N, Farre R, Gozal D . Sleep Apnea Morbidity: A Consequence of Microbial-Immune Cross-Talk?. Chest. 2018; 154(4):754-759. DOI: 10.1016/j.chest.2018.03.001. View

Zhang H, Liu G, Zhou W, Zhang W, Wang K, Zhang J . Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice. Sci Rep. 2019; 9(1):6509. PMC: 6482143. DOI: 10.1038/s41598-019-42994-1. View

Lu D, Wang J, Zhang H, Shan Q, Zhou B . Renal denervation improves chronic intermittent hypoxia induced hypertension and cardiac fibrosis and balances gut microbiota. Life Sci. 2020; 262:118500. DOI: 10.1016/j.lfs.2020.118500. View

Zhang F, Chen H, Zhang R, Liu Y, Kong N, Guo Y . 5-Fluorouracil induced dysregulation of the microbiome-gut-brain axis manifesting as depressive like behaviors in rats. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(10):165884. DOI: 10.1016/j.bbadis.2020.165884. View

10.

Langille M, Zaneveld J, Caporaso J, McDonald D, Knights D, Reyes J . Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013; 31(9):814-21. PMC: 3819121. DOI: 10.1038/nbt.2676. View

11.

Maslowski K, Vieira A, Ng A, Kranich J, Sierro F, Yu D . Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009; 461(7268):1282-6. PMC: 3256734. DOI: 10.1038/nature08530. View

12.

Lucking E, OConnor K, Strain C, Fouhy F, Bastiaanssen T, Burns D . Chronic intermittent hypoxia disrupts cardiorespiratory homeostasis and gut microbiota composition in adult male guinea-pigs. EBioMedicine. 2018; 38:191-205. PMC: 6306383. DOI: 10.1016/j.ebiom.2018.11.010. View

13.

Allahdadi K, Walker B, Kanagy N . Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension. 2005; 45(4):705-9. DOI: 10.1161/01.HYP.0000153794.52852.04. View

14.

Gabryelska A, Lukasik Z, Makowska J, Bialasiewicz P . Obstructive Sleep Apnea: From Intermittent Hypoxia to Cardiovascular Complications via Blood Platelets. Front Neurol. 2018; 9:635. PMC: 6085466. DOI: 10.3389/fneur.2018.00635. View

15.

Sauer A, Cole R, Jensen B, Pal J, Sharma N, Yehya A . Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2018; 24(2):167-176. PMC: 6394573. DOI: 10.1007/s10741-018-9757-1. View

16.

Yandrapalli S, Hasan Khan M, Rochlani Y, Aronow W . Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther Adv Cardiovasc Dis. 2018; 12(8):217-231. PMC: 6041873. DOI: 10.1177/1753944718784536. View

17.

Moreno-Indias I, Torres M, Montserrat J, Sanchez-Alcoholado L, Cardona F, Tinahones F . Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur Respir J. 2014; 45(4):1055-65. DOI: 10.1183/09031936.00184314. View

18.

Durgan D, Ganesh B, Cope J, Ajami N, Phillips S, Petrosino J . Role of the Gut Microbiome in Obstructive Sleep Apnea-Induced Hypertension. Hypertension. 2015; 67(2):469-74. PMC: 4713369. DOI: 10.1161/HYPERTENSIONAHA.115.06672. View

19.

Yang T, Santisteban M, Rodriguez V, Li E, Ahmari N, Carvajal J . Gut dysbiosis is linked to hypertension. Hypertension. 2015; 65(6):1331-40. PMC: 4433416. DOI: 10.1161/HYPERTENSIONAHA.115.05315. View

20.

Sanada T, Hosomi K, Shoji H, Park J, Naito A, Ikubo Y . Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model. Pulm Circ. 2020; 10(3):2045894020929147. PMC: 7457673. DOI: 10.1177/2045894020929147. View